Efectividad de los inhibidores SGLT2 en tratamiento de la insuficiencia cardiaca en pacientes del Hospital General Guasmo Sur.

Abstract

Heart failure (HF) is a complex clinical disorder that occurs when the heart's ventricles are unable to fill with blood or pump it efficiently. This ventricular dysfunction is reflected in common symptoms such as shortness of breath, peripheral edema, and fatigue, which may be accompanied by signs such as increased pressure in the neck veins, abnormal lung sounds, or fluid retention in the extremities. It is linked to various cardiovascular risk factors and other diseases. Pharmacotherapy is essential in the treatment of heart failure. European and American guidelines recommend the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in this context, based on studies such as DAPA-HF, EMPAREG, EMPEROR-REDUCED, and others, which demonstrated benefits such as reduced cardiovascular mortality, fewer hospitalizations, improved glucose control, and kidney protection. These drugs significantly improve left ventricular ejection fraction (LVEF) in patients with heart failure, so it is of great importance and interest to evaluate their effectiveness in patients at Hospital General Guasmo Sur by measuring LVEF and those with comorbidities.